Puma Biotechnology, Inc.

PBYI

US74587V1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:28:00 2024-07-17 EDT			5-day change	1st Jan Change
3.89 ^USD	-1.52%		+28.95%	-9.47%

07-01	Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Value Index	CI
07-01	Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Completeness Index	CI

Puma Biotechnology, Inc. Primary Exchange Listing will Change to Nasdaq Global Market from New York Stock Exchange

January 03, 2017 at 12:00 am

Effective January 03, 2017, Puma Biotechnology, Inc. primary exchange listing will change to Nasdaq Global Market from New York Stock Exchange.

Latest news about Puma Biotechnology, Inc.

Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Value Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Completeness Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2000 Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000E Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000 Growth Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2500 Value Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000 Value Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2000 Value Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000E Growth Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2000 Growth Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2000 Dynamic Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Microcap Value Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2500 Growth Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 2500 Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000 Index	06-30	CI
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell 3000E Value Index	06-30	CI
Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	06-02	CI
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	05-17	RE
Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	05-02	CI
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	03-20	MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	03-20	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI

Chart Puma Biotechnology, Inc.

Duration

Period

More charts

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Puma Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.95 USD

Average target price

4.333 USD

Spread / Average Target

+9.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PUMA BIOTECHNOLOGY, INC.	-9.47%	191M
MODERNA, INC.	+24.48%	47.96B
IQVIA HOLDINGS INC.	+1.87%	42.45B
LONZA GROUP AG	+44.30%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.64%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.43%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.30%	14.56B
MEDPACE HOLDINGS, INC.	+47.22%	14.14B
BIO-TECHNE CORPORATION	+4.02%	12.58B

Other Biotechnology & Medical Research